EUVIMEDEUVIMED entdecken
Leserbrief

Comparative pharmacovigilance assessment of adverse events associated with the use of hydroxyurea, L‐glutamine, voxelotor, and crizanlizumab in sickle cell disease

Ming Chen iD, Jane S Hankins iD, Min Zhang, Kenneth I Ataga iD

American Journal of Hematology · 2024

DOI: 10.1002/ajh.27153 ↗

Kurz gefasst

Leserbrief in der Zeitschrift American Journal of Hematology, 2024. Verfasst von Ming Chen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Health Outcomes and Policy, University of Tennessee Health Science Center, Memphis, Tennessee, USA. Hauptthemen laut MEDLINE: Hydroxyurea, Anemia, Sickle Cell, Benzaldehydes, Pyrazines. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 6 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HydroxyureaAnemia, Sickle CellBenzaldehydesPyrazinesPyrazolesAntibodies, Monoclonal, HumanizedHumansGlutaminePharmacovigilance

Substanzen

HydroxyureacrizanlizumabvoxelotorGlutamineBenzaldehydesPyrazinesPyrazolesAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Institute of Health Outcomes and Policy, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
  • Center for Health System Improvement, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
  • Department of Global Pediatric Medicine, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • Department of Hematology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • Center for Sickle Cell Disease, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
  • Vanke School of Public Health, Tsinghua University, Beijing, China.

ORCID-Profile: Ming Chen, Jane S Hankins, Kenneth I Ataga

Zitieren

APA

Chen, M., Hankins, J. S., Zhang, M., & Ataga, K. I. (2024). Comparative pharmacovigilance assessment of adverse events associated with the use of hydroxyurea, L‐glutamine, voxelotor, and crizanlizumab in sickle cell disease. American Journal of Hematology. https://doi.org/10.1002/ajh.27153

Vancouver

Chen M, Hankins JS, Zhang M, Ataga KI. Comparative pharmacovigilance assessment of adverse events associated with the use of hydroxyurea, L‐glutamine, voxelotor, and crizanlizumab in sickle cell disease. American Journal of Hematology. 2024. doi:10.1002/ajh.27153

BibTeX
@article{Chen2024,
  author = {Chen, Ming and Hankins, Jane S and Zhang, Min and Ataga, Kenneth I},
  title = {Comparative pharmacovigilance assessment of adverse events associated with the use of hydroxyurea, L‐glutamine, voxelotor, and crizanlizumab in sickle cell disease},
  journal = {American Journal of Hematology},
  year = {2024},
  doi = {10.1002/ajh.27153}
}
Kostenlos starten →